Signal Genetics Miragen Therapeutics, Signal Genetics Complete Merger, New Financing Round Privately held Miragen will pick up Signal's Nasdaq listing, and the combined company is scheduled to begin trading today. Signal Genetics Regains Compliance With Nasdaq Listing Requirement As of Nov. 21 the company evidenced a closing bid price of its common stock in excess of the $1 minimum requirement for at least 10 consecutive trading days. Miragen Therapeutics, Signal Genetics Agree to Merge The combined company will be focused on Miragen's microRNA therapeutics programs, following the divestiture of Signal's molecular diagnostic assets. Signal Genetics Revenues Up 27 Percent on Record Test Volume Revenue from tests billed for clinical patients rose 93 percent year over year, the firm said, though its net loss widened to $2.8 million. Signal Genetics Reports Q4 Revenues Essentially Flat The company said sales of its MyPRS test for myeloma risk increased during the quarter, but full-year 2015 revenues fell because of increased R&D costs. Jan 6, 2016 Signal Genetics, MD Anderson Ink Sponsored Research Agreement Oct 20, 2015 Additional PPOs to Cover Signal Genetics Multiple Myeloma Test Sep 8, 2015 Signal Genetics, Moffitt Cancer Center Partner on Multiple Myeloma Research Aug 13, 2015 Signal Genetics' Q2 Revenues Slide 43 Percent on Test Order Decline Aug 5, 2015 Signal Genetics Signs Reimbursement Agreement with America's Choice Provider Network May 14, 2015 Signal Genetics Q1 Revenues Slide 41 Percent Apr 30, 2015 Signal Genetics Lab Nabs CAP Accreditation Mar 27, 2015 Signal Genetics Reports Flat 2014 Revenues Feb 23, 2015 Signal Genetics Closes $9M Public Offering of Stock Feb 17, 2015 Signal Genetics Prices $9M Public Offering of Stock Feb 2, 2015 FDA Grants Conditional IDE Approval of Signal Genetics' MyPRS Nov 17, 2014 Signal Genetics Q3 Revenues Move up 32 Percent Sep 24, 2014 Signal Extends Gene Array Testing Services Agreements with UAMS Aug 15, 2014 Signal Genetics Reports 18 Percent Increase in Q2 Revenues Aug 13, 2014 People in the News: Fadi Braiteh, Michael C. Cerio Premium Jun 30, 2014 New York State Approves Signal Genetics' Myeloma Test Jun 18, 2014 Signal Genetics Prices IPO at $10 per Share, Expects $8.5M in Gross Proceeds Jun 17, 2014 Signal Genetics Increases IPO Target to up to $12.1M May 16, 2014 Signal Genetics Lowers Expected IPO Proceeds to $9.3M; Q1 Revenues Flat Mar 19, 2014 Signal Genetics Files for $25M IPO Load More Breaking News In Brief This Week: Illumina, Personalis, Proteomedix, and More Ancient DNA Details Population Dynamics Within Andean Tiwanaku Civilization Genomic Data Spanning 2K Years Gives Glimpse of Etruscan Origins, Population Changes People in the News: New Appointments at Hologic, Akoya Biosciences, Caris Life Sciences, More At NSGC, Genetic Counselors Address Race-Based Medicine, Ways to Change New Products Posted to GenomeWeb: Becton Dickinson, Cosmos-ID, OncoDNA, More The Scan US Booster Eligibility Decision The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions. Arizona Bill Before Judge The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction. Additional Genes Wales is rolling out new genetic testing service for cancer patients, according to BBC News. Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.